A clinicopathological base study to control over-diagnosis in early breast cancer screening and advance compound noninvasive immunotherapy for early breast cancer
| Project/Area Number |
17K08707
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
Yamaguchi Rin 久留米大学, 医学部, 准教授 (10309750)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Keywords | 乳癌 / サブタイプ / 過剰診断 / HER2陽性 / 腫瘍浸潤リンパ球 / DCIS / コメド壊死 / 複合免疫療法 / HER2陽性乳癌 / Andorogen receptor / Estrogen receptor / 術前補助療法 / 病理学的完全寛解 / 腫瘍周囲リンパ球浸潤 / Comedo壊死 / Androgen receptor / 乳癌検診 / 非浸潤癌 / 石灰化カテゴリー / 病理学 |
|---|
| Outline of Final Research Achievements |
Breast cancer (BC) is investigated from not only histological viewpoints, but also the subtypes. We examined how BC progresses from early (in situ) diagnosis to invasion by the subtypes (luminal, Her2, triple negative), as well from the histological viewpoint of the immune response to control over-diagnosis and over-treatment in early BC screening. In early BC, in situ Her2 BCs have high-grade cancer cells with comedo necrosis and there is a pathway of invasion by the response of tumor-infiltrating lymphocytes, which are different from other subtypes. Invasive Her2 BCs are revealed to divide largely into ER positive and negative depending on pathological, morphological, and immunological viewpoints. We believe that our results can contribute to the control of over-diagnosis and over-treatment in early BC screening and advance compound noninvasive immunotherapy for early BC.
|
| Academic Significance and Societal Importance of the Research Achievements |
高異型度上皮内乳癌が浸潤する際に免疫応答による経路が明らかになり、さらに通常高異型度癌が有するコメド壊死がマンモグラフィなど画像による石灰化に反映することから、元来予後不良であったHer2陽性や高異型度乳癌の早期発見に繋がることが示唆された。浸潤性Her2陽性乳癌ではER陽性と陰性群で病理・形態学的・免疫応答の点においてに大きく二分されることが明らかとなり、他サブタイプとの進展、浸潤の差異、類似点から、更なる早期発見や治療指針にも寄与できる。また、今後の複合免疫療法など新たなる治療にも繋がる。我々の研究結果は、目的とした検診の過剰診断抑制や今後の乳癌治療指針への大きな貢献を可能とする。
|
Report
(4 results)
Research Products
(58 results)
-
-
[Journal Article] iverse histomorphology of HER2-positive breast carcinomas based on differential ER expression.2020
Author(s)
Akashi M, Yamaguchi R, Kusano H, Obara H, Yamaguchi M, Toh U, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H.
-
Journal Title
Histopathology
Volume: 76
Issue: 4
Pages: 560-571
DOI
Related Report
Peer Reviewed
-
[Journal Article] Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.2020
Author(s)
Kanai A, McNamara KM, Iwabuchi E, Miki Y, Onodera Y, Guestini F, Khalid F,Sagara Y, Ohi Y, Rai Y, Yamaguchi R, Tanaka M, Miyashita M, Ishida T, Sasano H.
-
Journal Title
Breast Cancer Res Treat
Volume: 180
Issue: 1
Pages: 97-110
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Genomic characterisation of breast fibroepithelial lesions in an international cohort.2019
Author(s)
Md Nasir ND, Ng CCY, Rajasegaran V, Wong SF, Liu W, Ng GXP, Lee JY, Guan P,Lim JQ, Thike AA, Koh VCY, Loke BN, Chang KTE, Gudi MA, Lian DWQ, Madhukumar P,Tan BKT, Tan VKM, Wong CY, Yong WS, Ho GH, Ong KW; International Fibroepithelial Consortium, Tan P, Teh BT, Tan PH
-
Journal Title
J Pathol
Volume: 249
Issue: 4
Pages: 47-460
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] 乳腺腫瘍学2020
Author(s)
堀井理絵、大井恭代、坂谷貴司、山口 倫。
Total Pages
28
Publisher
日本乳癌学会
Related Report
-
-
-
-
-
-
-
-
